Human antibody 2G12 neutralizes a broad range of HIV-1 isolates. Hence, molecular characterization of its epitope, which corresponds to a conserved cluster of oligomannoses on the viral envelope glycoprotein gp120, is a high priority in HIV vaccine design. A prior crystal structure of 2G12 in complex with Man 9GlcNAc2 highlighted the central importance of the D1 arm in antibody binding. To characterize the specificity of 2G12 more precisely, we performed solution-phase ELISA, carbohydrate microarray analysis, and cocrystallized Fab 2G12 with four different oligomannose derivatives (Man 4, Man5, Man7, and Man8) that compete with gp120 for binding to 2G12. Our combined studies reveal that 2G12 is capable of binding both the D1 and D3 arms of the Man 9GlcNAc2 moiety, which would provide more flexibility to make the required multivalent interactions between the antibody and the gp120 oligomannose cluster than thought previously. These results have important consequences for the design of immunogens to elicit 2G12-like neutralizing antibodies as a component of an HIV vaccine.
T
here is widespread agreement that the most promising approach to contain the ongoing HIV pandemic is through the development of an effective vaccine (1, 2) . However, HIV vaccine design has faced many difficulties including, prominently, the lack of an immunogen able to elicit broadly neutralizing antibodies (Abs). The feasibility of developing such an immunogen is suggested by a small panel of broadly neutralizing human monoclonal antibodies (mAbs) that have been isolated from seropositive donors (3) . One of these Abs, 2G12, recognizes a conserved and unusually dense cluster of oligomannose residues on the ''silent face'' of gp120, the major envelope protein of HIV-1 (4, 5) . Many lectins have been identified that can bind to envelope and act antivirally, but 2G12 remains the only known anti-carbohydrate protein that has been specifically elicited to HIV-1 in an adaptive immune response (6) . 2G12 has an unusual architecture in which the arms of the IgG swap variable heavy domains, creating a domainswapped dimer of Fabs (7) . The crystal structure of Fab 2G12 complexed with Man 9 GlcNAc 2 indicated that the conventional Ab-binding sites are occupied by the D1 arms of the Man 9 GlcNAc 2 moieties (1; Fig. 1 ) (7) . The terminal Man␣1-2Man residues of the D1 branch account for 85% of the Fab contacts to Man 9 GlcNAc 2 , although the disaccharide by itself is 50-fold less potent in binding to 2G12 than Man 9 GlcNAc 2 (7) .
Based on these structural results, several initiatives have been launched to design novel immunogens that will elicit 2G12-like Abs (8) (9) (10) (11) (12) . Recently, we described the design and synthesis of novel antigens, oligomannoses 2-6 ( Fig. 1) , that bind to mAb 2G12 (13) . The Man␣1-2Man-containing oligomannoses 4, 5, and 6 were identified as new epitope mimics that inhibit the binding of gp120 to mAb 2G12 as well as, or better than, Man 9 GlcNAc 2 (13) . Encouraged by this result, we now report the design and synthesis of three additional antigens, oligomannoses 7, 8, and 9 ( Fig. 1) , using the reactivity-based, one-pot synthesis method (14) (15) (16) (17) (18) . The ligand specificity of 2G12 was further probed by studying the ability of these oligomannoses to (i) inhibit the binding of 2G12 to gp120 in solution-phase ELISA (4) and (ii) bind 2G12 in microtiter plate-based or glass-slide assays (19) (20) (21) (22) (23) (24) . We also determined the crystal structures of Fab 2G12 bound to four of these synthetic oligomannoses (4, 5, 7, and 8). Our biochemical, biophysical, and crystallographic results reveal that Fab 2G12 can recognize the terminal Man␣1-2Man of both the D1 and D3 arms of Man 9 GlcNAc 2 . These data confirm that 2G12 is highly specific for terminal Man␣1-2Man, but in the context of a broader range of solution of the amino-functionalized disulfide and alkyne containing linker (see Scheme 3) containing 5% diisopropylethylamine and incubated overnight at 4°C. The microtiter plate then was washed with 2 ϫ 200 l of methanol and 2 ϫ 200 l of water. Next, 200-l solutions of azido-functionalized oligomannose derivatives 21-25 at varying concentrations from 0 to 500 M in 5% diisopropylethylamine͞methanol were introduced. A sprinkle of copper(I) iodide was added, and the contents were allowed to react overnight at 4°C. The next day, the contents were removed, and the plates were washed with 2 ϫ 200 l of methanol and 2 ϫ 200 l of water. The plates then were blocked with 0.1% Tween 20 solution in Hepes buffer (pH 7.5) at 4°C for 1 h and then washed with 3 ϫ 200 l of Hepes buffer. Next, 200 l of a 1 g͞ml solution of 2G12 Ab in 0.1% Tween 20͞PBS buffer (pH 7.4) was added to the wells for a 1-h incubation at 4°C and then washed with 2 ϫ 200 l of PBS buffer (pH 7.4). At this point, 200 l of FITC-tagged goat antihuman IgG Ab (10 g͞ml in PBS; Calbiochem) was added for 1 h at 4°C, and the wells then were washed with 2 ϫ 200 l of PBS buffer (pH 7.4). Detection of the FITC-tagged secondary Ab was performed in 200 l of water by using a fluorescence plate reader. The resulting data yielded the oligomannose-2G12 binding isotherms, and Scatchard plot analysis was implemented in the determination of dissociation constants (24) .
2G12 Purification, Crystallization, Structure Determination, and Analysis. Human mAb 2G12 (IgG1, ) was produced by recombinant expression in CHO cells. Fab fragments were produced by digestion of the Ig with papain followed by purification on protein A and G columns, and then concentrated to Ϸ30 mg͞ml. For each complex (Man 4 , Man 5 , Man 7 , and Man 8 ), the solid sugar ligand was added to the Fab solution to saturation. For crystallization, 0.6 l of protein plus sugar were mixed with an equal volume of reservoir solution. All crystals were grown by the sitting drop vapor diffusion method with a reservoir volume of 1 ml. Fab 2G12 plus Man 4 crystals were grown with a reservoir solution of 27% polyethylene (26) . The Matthews' coefficients of the asymmetric unit suggested that the Fab 2G12 plus Man 4 data contained a single Fab plus sugar complex, whereas the asymmetric unit of the other complexes consisted of two Fab plus sugar complexes. The model building was performed with TOM͞FRODO (27) and refined with CNS (Version 1.1; ref. 28) and REFMAC by using TLS refinement (29) , using all measured data (with F Ͼ 0.0 ). Tight noncrystallographic symmetry restraints were applied initially but were released gradually during refinement. An R free test set (5%) was maintained throughout the refinement. Data collection and refinement results are summarized in Table 1 .
Diffraction data for Fab 2G12 in complex with Man 4 suffered from severe anisotropy despite the 2.0-Å diffraction limit. Although we report on the measured data observed to 2.0 Å (I͞ Ͼ 2.0 and a completeness of 88% in the highest resolution shell of 2.05-2.00 Å), anisotropic diffraction, which is significant beyond 2.75 Å, leads to modest R values. However, the electron density is very well defined and more easily interpretable at higher resolution. Refinement of the Man 4 structure at a lower resolution of 2.75 Å yields slightly better R crys and R free values of 21.9% and 28.2%, respectively, but with significantly poorer-quality electron density maps. Thus, the higher-resolution structure is reported.
Potential H bonds and van der Waals contacts were evaluated by using the program CONTACSYM (30) . Buried molecular surface areas were measured by using the program MS (31) .
Results and Discussion
Synthesis of Man7 7, Man8 8, and Man9 9. The synthesis of high mannose-type oligosaccharides, Man 9 GlcNAc 2 and its analogues, has been extensively explored (11, (32) (33) (34) (35) (36) (37) by using a convergent approach that is generally more concise and efficient. The one-pot programmable relative reactivity value (RRV) assay (14) revealed that thioglycoside disaccharide building block 10 (RRV ϭ 790) is less reactive than compound 11 (RRV ϭ 3638), 15 (RRV ϭ 3137), and 18 (RRV ϭ 4398). Thus, the trichloroacetimidate group, which is a more reactive leaving group than p-methylphenylthio, was implemented.
Synthesis of Man 7 7 is described in Scheme 1 and was performed as described in ref. 38 . Thioglycoside disaccharide building block 10 Scheme 1.
Scheme 2.
was converted to its trichloroacetimidate derivative, which was activated with tert-butyldimethylsilyl trifluoromethansulfonate (TBDMSOTf) for glycosylation with building block 11 to give trisaccharide building block 12 in good yield (75% over three steps). Convergent synthesis of Man 7 7 in good yield (85%) was achieved by glycosylation of tetrasaccharide acceptor 13 with trisaccharide donor 12 by using the sodium iodide symporter͞trifluoromethane-sulfonic acid promoting system in anhydrous CH 2 Cl 2 at Ϫ25°C (39). Excellent Man␣1-6Man selectivity was controlled by the presence of the tert-butyldimethylsilyl group at the 2-position of trisaccharide donor 12. Global deprotection of protected Man 7 14 was achieved smoothly through desilylation with tetrabutylammonium fluoride͞ AcOH buffer (11) , deacetylation, and hydrogenolysis to afford unprotected Man 7 7 (60% in three steps).
By using a similar strategy, syntheses of Man 8 8 and Man 9 9 were performed as shown in Scheme 2. Thioglycoside disaccharide building block 10 was converted to its trichloroacetimidate derivative and glycosylated by using building block 15 (1.1 equivalent) or 18 (0.45 equivalent) to give the tetrasaccharide building block 16 (75% over three steps) and pentasaccharide building block 19 (65% over three steps). In the convergent synthesis of Man 8 8 and Man 9 9, the Man␣1-6Man selectivity was controlled by implementing Seeberger's protocol (36) . Thioglycoside tetrasaccharide 16 and pentasacharride 19 were converted to the corresponding trichloroimidates, which were coupled to tetrasaccharide 13 to give protected Man 8 17 (75% over three steps) and Man 9 20 (75% over three steps). Global deprotection of protected Man 8 17 and Man 9 20 was achieved through deacetylation and hydrogenolysis to afford unprotected Man 8 8 (60% in two steps) and Man 9 9 (60% in two steps).
Solution-Phase ELISA Analysis of Oligomannose 1-9 Inhibition of 2G12
Binding. Man 9 GlcNAc 2 1 (7) and deprotected oligomannoses 2-6 (13) and 7-9 were evaluated for their ability to inhibit the interaction between 2G12 and gp120 in a solution-phase ELISA. These results ( Fig. 2 ) confirmed that terminal Man␣1-2Man is critical for binding. All of the oligomannoses that contain a Man␣1-2Man␣1-2Man motif (which corresponds to the D1 arm of Man 9 GlcNAc 2 ) are capable of inhibiting 2G12 binding at similar levels to the intact Man 9 GlcNAc 2 moiety. However, 2G12 does not readily recognize Man␣1-2Man␣1-3Man, because oligomannose 3 does not inhibit effectively at lower concentrations (15.8% at 0.5 mM). Oligomannose 5, which is similar to oligomannose 3, but contains the Man␣1-2Man␣1-6Man motif, is capable of inhibition (37.7% at 0.5 mM). These results suggest that 2G12 recognizes Man␣1-2Man in the context of the D1 arm (Man␣1-2Man␣1-2Man) or the D3 arm (Man␣1-2Man␣1-6Man), but not the D2 arm (Man␣1-2Man␣1-3Man). Overall, many of the oligomannose derivatives can compete for binding of Man 9 GlcNAc 2 and, therefore, may serve as building blocks for potential immunogens to elicit 2G12-like Abs.
Carbohydrate Microarray Analysis. Recently, we reported the study of a panel of carbohydrate epitopes for interaction with 2G12 by using covalent microtiter plates display (21, 23) by converting the amine-containing oligomannoses 4, 5, 7, 8, and 9 to the corresponding azide derivatives 21, 22, 23, 24, and 25 (40) . These derivatives then were covalently attached to a microplate-immobilized cleavable linker via the Cu(I)-catalyzed 1,3-dipolar cycloaddition reaction (23) . K d values for the interaction of 2G12 with oligomannoses 4, 5, 7, 8, and 9 were determined by using a microtiter-based assay with detection through a fluorescent secondary Ab (23) (Fig. 2) . The K d values were as follows: oligomannose 4, 0.1 M; 5, 0.1 M; 7, 0.7 M; 8, 1.3 M; and 9, 1.0 M. Significant enhancement of the binding affinity of these compounds in microarray studies may be explained by multivalent interactions of the oligomannoses with 2G12 that mimic the cluster of oligomannoses on the surface of gp120. The smaller oligomannose derivatives especially benefit from multivalent display. Thus, this system may be an effective model for studying binding events involving carbohydrates presented on a surface, such as that of a virus.
Crystal Structure of Fab 2G12 with Man4. In the crystal structure of Fab 2G12 in complex with Man 4 (oligomannose 4), the Man 4 sugar is located in the combining site of the Ab and has extremely well defined electron density (Fig. 3A) . As expected, the Man␣1-2Man terminus of the sugar (consisting of mannoses D1 and C) binds end-on in a cleft in the binding site. An overlay with a previous structure of Fab 2G12 plus Man 9 GlcNAc 2 (7) shows that Man 4 binds with a similar geometry to the D1 arm of Man 9 GlcNAc 2 ( Fig.  3B) that correlates with the biochemical data that indicate Man 4 binds as well as the entire Man 9 GlcNAc 2 moiety (13). The crystal structure of the Fab 2G12-Man 4 complex is of higher resolution and allows better characterization of the interactions between Fab and sugar ligand. A total of 51 van der Waals interactions and 15 H bonds are formed on complex formation; 292 Å 2 of molecular surface is buried on Fab 2G12 and 294 Å 2 is buried on the sugar in the complex. Although the bulk of the interactions are with Man␣1-2Man (mannoses D1 and C), three H bonds are made between 2G12 and mannose 4, two of which are water-mediated (Fig. 3C) . Tyr L94 H bonds to the O3 oxygen of mannose 4, whereas water molecules coordinate between the O5 of mannose D1 and the O3 of mannose 4, and between Tyr H56 and the O4 of mannose 4.
Crystal Structure of Fab 2G12 with Man5. Man 5 (oligomannose 5) is the structural equivalent of the D2 and D3 arms of Man 9 GlcNAc 2 . 2G12 binds to Man 5 with similar apparent affinity as Man 4 and Man 9 GlcNAc 2 (13). The Man␣1-2Man moieties (mannoses D3 and B), which correspond to the D3 arm of Man 9 GlcNAc 2 , are well ordered in the primary combining site (Fig. 4A) . The other Man␣1-2Man (mannoses D2 and A) branch, which corresponds to the D2 arm of Man 9 GlcNAc 2 , points away from the binding site, confirming biochemical studies that suggest 2G12 recognizes the D3 arm in preference to D2. 302 Å 2 of molecular surface is buried on Fab 2G12 and 307 Å 2 is buried on Man 5 upon complex formation. Unlike Man 4 (D1 arm) binding, no additional H bonds are made to sugars other than with the terminal Man␣1-2Man.
Crystal Structure of Fab 2G12 with Man7. Man 7 (oligomannose 7) is the structural equivalent of the D1 and D2 arms of Man 9 GlcNAc 2 . One Man 7 moeity is bound to each Ab-combining site of the 2G12 domain-swapped Fab dimer, but only four of the seven sugars are clearly interpretable in the electron density maps. In general, sugars are extremely flexible and give rise to poorly defined electron density unless they are somehow ''fixed,'' either by direct binding along the length of the entire sugar chain or through the incorporation of the sugar into the crystal lattice. In this case, as opposed to the Man 8 (see below) and Man 9 GlcNAc 2 (1) sugars that crosslink the crystals together, and hence give well-defined sugar electron density, no such cross-linking occurred.
However, the D1 arm, and not the D2 arm, can be clearly resolved in the Ab-combining site. This Man 7 moiety overlaps well with the corresponding Man 4 structure and the D1 arm of the Man 9 GlcNAc 2 structure (8). The interactions between 2G12 and Man 7 are similar to those between 2G12 and Man 4 , including the H bonds with mannose 4.
Crystal Structure of Fab 2G12 with Man8. Man 8 (oligomannose 8) is nearly equivalent to the entire Man 9 moeity, with only the terminal sugar of the D2 arm missing. In the Man 8 crystal structure, the two primary combining sites of the domain-swapped dimer each interact with a Man 8 moeity but bind to different arms of the sugar. One binding site interacts with the D1 arm, whereas the other is occupied by the D3 arm (Fig. 4B) . In this crystal lattice, the Man 8 sugar cross-links the crystal and is, therefore, well ordered, as indicated by its well-resolved electron density. Each Man 8 sugar moiety in the crystal has its D1 arm bound in one of the two combining sites of an Fab 2G12 dimer, while its D3 arm is bound in one of the combining sites of a crystallographically related Fab 2G12 dimer (Fig. 4C) 
Conclusions
We have expanded on our previous synthesis and study of oligomannose derivatives using the reactivity-based one-pot selfcondensation reaction. We have prepared three previously undescribed Man␣1-2Man-containing oligomannose compounds, Man 7 7, Man 8 8, and Man 9 9, that have reactivity with broadly neutralizing HIV-1 Ab 2G12. Overall, the carbohydrate specificity of 2G12 is less restrictive than originally believed (7). The combined biochemical, biophysical, and crystallographic evidence clearly indicates that 2G12 can bind to the Man␣1-2Man at the termini of both the D1 and D3 arms of an oligomannose sugar. In the Man 4 , Man 7 , and Man 8 crystal structures, 2G12 interacts with the D1 arm, whereas in the Man 5 and Man 8 crystal structures, the D3 arm can also bind in the combining site (Fig. 5) . Therefore, 2G12 can bind not only the D1 arms from two different N-linked oligomannoses on gp120 but also to both the D1 and D3 arms from different sugars within the oligomannose constellations on gp120. This mode of recognition would enhance binding to a cluster of oligomannose moieties and relax the constraint of an exact match of the oligomannose moieties with respect to the multivalent binding site of the Ab. Nevertheless, despite this increased potential for multivalent interaction, 2G12 is highly restricted to oligomannose cluster binding on gp120, because no significant binding to ''self'' proteins has been observed.
The 2G12 Ab can neutralize a broad range of HIV-1 isolates. The results presented here reveal more precisely the carbohydrate specificity of this Ab. This deeper understanding of the 2G12-oligomannose interaction can now be applied to carbohydratebased immunogen design, because the nature of the mannose building blocks needed to design a multivalent oligomannose presentation for immunization trials has been established. 
Supporting Text
General. All chemicals were purchased as reagent grade and used without further purification. Dichloromethane (CH 2 Cl 2 ) were distilled over calcium hydride.
Tetrahydrofuran (THF) and ether were distilled over sodium metal/benzophenone ketyl.
Anhydrous DMF was obtained from Aldrich. Molecular sieves (MS) for glycosylation were AW300 (Aldrich) and activated by microwave. Reactions were monitored with analytical thin layer chromatography (TLC) in EM silica gel 60 F254 plates and visualized under UV (254 nm) and/or staining with acidic ceric ammonium molybdate or ninhydrin. Flash column chromatography was performed on silica gel 60 Geduran (35-75 µm; EM Science).
1 H NMR spectra were recorded on a DRX-500 (500 MHz; Bruker, Billerica, MA) spectrometer at 20°C. Chemical shifts (δ ppm) were assigned according to the internal standard signal of tetramethylsilane in CDCl 3 (δ = 0 ppm). 13 C NMR spectra were obtained by using the attached proton test (APT) on a Bruker DRX-500 (125 MHz) spectrometer and were reported in δ ppm scale by using the signal of CDCl 3 (δ = 77.00 ppm). Coupling constants (J) are reported in hertz. Splitting patterns are described by using the following abbreviations: s, singlet; brs, broad singlet; d, doublet; t, triplet; q, quartet; m, multiplet. 1 H NMR spectra are reported in the following order: chemical shift, multiplicity, coupling constant(s), and number(s) of proton. 
Synthesis of monosaccharide building block (11)

Synthesis of disaccharide building block 15
Disaccharide Building Block (15).
To a stirred solution of compound 10 (200 mg, 0.3 mmol) in acetone (5 ml) was added N-bromosuccinimide (NBS) (2 equiv.) at 0°C for 30 min. EtOAc (50 ml) was added to the solution, which was washed with water (10 ml × 3).
The organic layer was dried over Na 2 Scheme 6. Reagents and conditions: a, TBDMS-Cl, imidazole, DMF, rt, 1h; b, BnBr, NaH, DMF, 0°C to rt, 2 h; c, TBAF, THF, rt, 2 h, 60% over three steps.
Monosaccharide Building Block (14).
To a stirred solution of 30 (2.86 g, 10 mmol) in DMF (10 ml) was added TBDMS-Cl (2.5 equiv.) and imidazole (6 equiv.). The reaction mixture was stirred at rt for 1 h then was diluted with EtOAc (300 ml) and quenched with H 2 O (60 ml). The organic phase was washed with water (60 ml × 2) and brine (60 ml × 1) and dried over anhydrous Na 2 SO 4 . The solvent was removed under reduced pressure to
give the residue, which was passed through a pad of silica gel and washed with Hexane:EtOAc (7:1, vol/vol). The solvent was removed under reduced pressure to give colorless oil. The oil was dissolved in DMF (20 ml), and then BnBr (2.5 equiv.) and NaH 
